| Dr David Adrian Lilienstein, MD | |
|
1425 S Main St, Walnut Creek, CA 94596-5318 | |
| (925) 295-6723 | |
| Not Available |
| Full Name | Dr David Adrian Lilienstein |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1425 S Main St, Walnut Creek, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750571212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A100009 (California) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.
Few strands of bacteria have achieved such a central place in public consciousness as Bacillus anthracis, the bacteria which causes Anthrax. While today it is a feared weapon of bioterrorism Bacillus anthracis has played a significant historical role, especially through the research of the celebrated 19th century scientists Robert Koch and Louis Pasteur, in shaping our understanding of infectious diseases and immunology
Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Adrian Lilienstein, MD 1425 S Main St, Walnut Creek, CA 94596-5318 Ph: (925) 295-6723 | Dr David Adrian Lilienstein, MD 1425 S Main St, Walnut Creek, CA 94596-5318 Ph: (925) 295-6723 |
News Archive
In an analysis of more than 120,000 women diagnosed with and treated for early-stage breast cancer, researchers from The University of Texas MD Anderson Cancer Center determined the rate of additional breast biopsies needed for these patients during their follow-up care.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, today provided an update on its Phase 2 clinical trial for the use of its lead compound, NVC-422, to prevent urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.
Few strands of bacteria have achieved such a central place in public consciousness as Bacillus anthracis, the bacteria which causes Anthrax. While today it is a feared weapon of bioterrorism Bacillus anthracis has played a significant historical role, especially through the research of the celebrated 19th century scientists Robert Koch and Louis Pasteur, in shaping our understanding of infectious diseases and immunology
Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).
› Verified 3 days ago
Brook Andrew Woolley, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1425 S Main St, Emergency Medicine Department, Walnut Creek, CA 94596 Phone: 925-295-5100 | |
Malcolm C Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Alice Decker Hunter, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Seigfred P. Jalalon, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1450 Treat Blvd # 160, Walnut Creek, CA 94597 Phone: 925-296-9000 | |
Theodore Ira Kloth, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1601 Ygnacio Valley Rd, Walnut Creek, CA 94598 Phone: 925-939-3000 | |
Stephanie Carlson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 | |
Michael R. Lozano, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1425 S Main St, Walnut Creek, CA 94596 Phone: 925-295-4000 |